Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Pterostilbene Suppresses Ovarian Cancer Growth via Induction of Apoptosis and Blockade of Cell Cycle Progression Involving Inhibition of the STAT3 Pathway.

Wen W, Lowe G, Roberts CM, Finlay J, Han ES, Glackin CA, Dellinger TH.

Int J Mol Sci. 2018 Jul 7;19(7). pii: E1983. doi: 10.3390/ijms19071983.

2.

Snail knockdown reverses stemness and inhibits tumour growth in ovarian cancer.

Hojo N, Huisken AL, Wang H, Chirshev E, Kim NS, Nguyen SM, Campos H, Glackin CA, Ioffe YJ, Unternaehrer JJ.

Sci Rep. 2018 Jun 7;8(1):8704. doi: 10.1038/s41598-018-27021-z.

3.

Chick chorioallantoic membrane assay as an in vivo model to study the effect of nanoparticle-based anticancer drugs in ovarian cancer.

Vu BT, Shahin SA, Croissant J, Fatieiev Y, Matsumoto K, Le-Hoang Doan T, Yik T, Simargi S, Conteras A, Ratliff L, Jimenez CM, Raehm L, Khashab N, Durand JO, Glackin C, Tamanoi F.

Sci Rep. 2018 Jun 4;8(1):8524. doi: 10.1038/s41598-018-25573-8.

4.

Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer.

Shahin SA, Wang R, Simargi SI, Contreras A, Parra Echavarria L, Qu L, Wen W, Dellinger T, Unternaehrer J, Tamanoi F, Zink JI, Glackin CA.

Nanomedicine. 2018 Apr 14;14(4):1381-1394. doi: 10.1016/j.nano.2018.04.008. [Epub ahead of print]

5.

Tyrosine kinase receptor c-ros-oncogene 1 inhibition alleviates aberrant bone formation of TWIST-1 haploinsufficient calvarial cells from Saethre-Chotzen syndrome patients.

Camp E, Anderson PJ, Zannettino ACW, Glackin CA, Gronthos S.

J Cell Physiol. 2018 Sep;233(9):7320-7332. doi: 10.1002/jcp.26563. Epub 2018 Apr 16.

PMID:
29663378
6.

Pterostilbene, a natural phenolic compound, synergizes the antineoplastic effects of megestrol acetate in endometrial cancer.

Wen W, Lowe G, Roberts CM, Finlay J, Han ES, Glackin CA, Dellinger TH.

Sci Rep. 2017 Oct 6;7(1):12754. doi: 10.1038/s41598-017-12922-2.

7.

Disruption of TWIST1-RELA binding by mutation and competitive inhibition to validate the TWIST1 WR domain as a therapeutic target.

Roberts CM, Shahin SA, Loeza J, Dellinger TH, Williams JC, Glackin CA.

BMC Cancer. 2017 Mar 10;17(1):184. doi: 10.1186/s12885-017-3169-9.

8.

Nanoparticle delivery of siRNA against TWIST to reduce drug resistance and tumor growth in ovarian cancer models.

Roberts CM, Shahin SA, Wen W, Finlay JB, Dong J, Wang R, Dellinger TH, Zink JI, Tamanoi F, Glackin CA.

Nanomedicine. 2017 Apr;13(3):965-976. doi: 10.1016/j.nano.2016.11.010. Epub 2016 Nov 25.

PMID:
27890656
9.

TWIST1 drives cisplatin resistance and cell survival in an ovarian cancer model, via upregulation of GAS6, L1CAM, and Akt signalling.

Roberts CM, Tran MA, Pitruzzello MC, Wen W, Loeza J, Dellinger TH, Mor G, Glackin CA.

Sci Rep. 2016 Nov 23;6:37652. doi: 10.1038/srep37652.

10.

15-Methylene-Eburnamonine Kills Leukemic Stem Cells and Reduces Engraftment in a Humanized Bone Marrow Xenograft Mouse Model of Leukemia.

Gunasekara DC, Zheng MM, Mojtahed T, Woods JR, Fandy TE, Riofski MV, Glackin CA, Hassan HE, Kirshner J, Colby DA.

ChemMedChem. 2016 Sep 28. doi: 10.1002/cmdc.201600334. [Epub ahead of print]

11.

Twist-1 Enhances Bone Marrow Mesenchymal Stromal Cell Support of Hematopoiesis by Modulating CXCL12 Expression.

Arthur A, Cakouros D, Cooper L, Nguyen T, Isenmann S, Zannettino AC, Glackin CA, Gronthos S.

Stem Cells. 2016 Feb;34(2):504-9. doi: 10.1002/stem.2265. Epub 2015 Dec 31.

12.

Mesoporous silica nanoparticle delivery of chemically modified siRNA against TWIST1 leads to reduced tumor burden.

Finlay J, Roberts CM, Dong J, Zink JI, Tamanoi F, Glackin CA.

Nanomedicine. 2015 Oct;11(7):1657-66. doi: 10.1016/j.nano.2015.05.011. Epub 2015 Jun 24.

13.

RNA-based TWIST1 inhibition via dendrimer complex to reduce breast cancer cell metastasis.

Finlay J, Roberts CM, Lowe G, Loeza J, Rossi JJ, Glackin CA.

Biomed Res Int. 2015;2015:382745. doi: 10.1155/2015/382745. Epub 2015 Feb 11.

14.

The histone demethylase jumonji coordinates cellular senescence including secretion of neural stem cell-attracting cytokines.

Perrigue PM, Silva ME, Warden CD, Feng NL, Reid MA, Mota DJ, Joseph LP, Tian YI, Glackin CA, Gutova M, Najbauer J, Aboody KS, Barish ME.

Mol Cancer Res. 2015 Apr;13(4):636-50. doi: 10.1158/1541-7786.MCR-13-0268. Epub 2015 Feb 4.

15.

Targeting the Twist and Wnt signaling pathways in metastatic breast cancer.

Glackin CA.

Maturitas. 2014 Sep;79(1):48-51. doi: 10.1016/j.maturitas.2014.06.015. Epub 2014 Jul 18. Review.

PMID:
25086726
16.

A reconstructed metastasis model to recapitulate the metastatic spread in vitro.

Parikh MR, Minser KE, Rank LM, Glackin CA, Kirshner J.

Biotechnol J. 2014 Sep;9(9):1129-39. doi: 10.1002/biot.201400121. Epub 2014 Jul 7.

17.

Spiking neural network connectivity and its potential for temporal sensory processing and variable binding.

Wall J, Glackin C.

Front Comput Neurosci. 2013 Dec 19;7:182. doi: 10.3389/fncom.2013.00182. eCollection 2013. No abstract available.

18.

Dkk-1 and IL-7 in plasma of patients with multiple myeloma prevent differentiation of mesenchymal stem cells into osteoblasts.

Nierste BA, Glackin CA, Kirshner J.

Am J Blood Res. 2014 Dec 15;4(2):73-85. eCollection 2014.

19.

TWIST1, A novel androgen-regulated gene, is a target for NKX3-1 in prostate cancer cells.

Eide T, Ramberg H, Glackin C, Tindall D, Taskén KA.

Cancer Cell Int. 2013 Jan 31;13(1):4. doi: 10.1186/1475-2867-13-4.

20.

Specific pomegranate juice components as potential inhibitors of prostate cancer metastasis.

Wang L, Ho J, Glackin C, Martins-Green M.

Transl Oncol. 2012 Oct;5(5):344-55. Epub 2012 Oct 1.

21.

TWIST1 associates with NF-κB subunit RELA via carboxyl-terminal WR domain to promote cell autonomous invasion through IL8 production.

Li S, Kendall SE, Raices R, Finlay J, Covarrubias M, Liu Z, Lowe G, Lin YH, Teh YH, Leigh V, Dhillon S, Flanagan S, Aboody KS, Glackin CA.

BMC Biol. 2012 Aug 14;10:73. doi: 10.1186/1741-7007-10-73.

22.

Genomic occupancy of HLH, AP1 and Runx2 motifs within a nuclease sensitive site of the Runx2 gene.

Hovhannisyan H, Zhang Y, Hassan MQ, Wu H, Glackin C, Lian JB, Stein JL, Montecino M, Stein GS, van Wijnen AJ.

J Cell Physiol. 2013 Feb;228(2):313-21. doi: 10.1002/jcp.22109.

23.

Cellular host responses to gliomas.

Najbauer J, Huszthy PC, Barish ME, Garcia E, Metz MZ, Myers SM, Gutova M, Frank RT, Miletic H, Kendall SE, Glackin CA, Bjerkvig R, Aboody KS.

PLoS One. 2012;7(4):e35150. doi: 10.1371/journal.pone.0035150. Epub 2012 Apr 23.

24.

Synchrony: a spiking-based mechanism for processing sensory stimuli.

Glackin C, Maguire L, McDaid L, Wade J.

Neural Netw. 2012 Aug;32:26-34. doi: 10.1016/j.neunet.2012.02.020. Epub 2012 Feb 14.

PMID:
22377659
25.

Role of CEACAM1, ECM, and mesenchymal stem cells in an orthotopic model of human breast cancer.

Samineni S, Glackin C, Shively JE.

Int J Breast Cancer. 2011;2011:381080. doi: 10.4061/2011/381080. Epub 2010 Nov 7. Erratum in: Int J Breast Cancer. 2011;2011:537380.

26.

Twist-1 induces Ezh2 recruitment regulating histone methylation along the Ink4A/Arf locus in mesenchymal stem cells.

Cakouros D, Isenmann S, Cooper L, Zannettino A, Anderson P, Glackin C, Gronthos S.

Mol Cell Biol. 2012 Apr;32(8):1433-41. doi: 10.1128/MCB.06315-11. Epub 2012 Jan 30.

27.

Human neural stem cell tropism to metastatic breast cancer.

Zhao D, Najbauer J, Annala AJ, Garcia E, Metz MZ, Gutova M, Polewski MD, Gilchrist M, Glackin CA, Kim SU, Aboody KS.

Stem Cells. 2012 Feb;30(2):314-25. doi: 10.1002/stem.784.

28.

The natural products parthenolide and andrographolide exhibit anti-cancer stem cell activity in multiple myeloma.

Gunn EJ, Williams JT, Huynh DT, Iannotti MJ, Han C, Barrios FJ, Kendall S, Glackin CA, Colby DA, Kirshner J.

Leuk Lymphoma. 2011 Jun;52(6):1085-97. doi: 10.3109/10428194.2011.555891. Epub 2011 Mar 21.

PMID:
21417826
29.

Receptive field optimisation and supervision of a fuzzy spiking neural network.

Glackin C, Maguire L, McDaid L, Sayers H.

Neural Netw. 2011 Apr;24(3):247-56. doi: 10.1016/j.neunet.2010.11.008. Epub 2010 Dec 7.

PMID:
21277162
30.

TWIST1 promotes invasion through mesenchymal change in human glioblastoma.

Mikheeva SA, Mikheev AM, Petit A, Beyer R, Oxford RG, Khorasani L, Maxwell JP, Glackin CA, Wakimoto H, González-Herrero I, Sánchez-García I, Silber JR, Horner PJ, Rostomily RC.

Mol Cancer. 2010 Jul 20;9:194. doi: 10.1186/1476-4598-9-194.

31.

Twist-ing cell fate: mechanistic insights into the role of twist in lineage specification/differentiation and tumorigenesis.

Cakouros D, Raices RM, Gronthos S, Glackin CA.

J Cell Biochem. 2010 Aug 15;110(6):1288-98. doi: 10.1002/jcb.22651. Review.

PMID:
20564230
32.

TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214.

Yin G, Chen R, Alvero AB, Fu HH, Holmberg J, Glackin C, Rutherford T, Mor G.

Oncogene. 2010 Jun 17;29(24):3545-53. doi: 10.1038/onc.2010.111. Epub 2010 Apr 19.

33.

Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival.

Gjerdrum C, Tiron C, Høiby T, Stefansson I, Haugen H, Sandal T, Collett K, Li S, McCormack E, Gjertsen BT, Micklem DR, Akslen LA, Glackin C, Lorens JB.

Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):1124-9. doi: 10.1073/pnas.0909333107. Epub 2009 Dec 28.

34.

Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies.

Frank RT, Edmiston M, Kendall SE, Najbauer J, Cheung CW, Kassa T, Metz MZ, Kim SU, Glackin CA, Wu AM, Yazaki PJ, Aboody KS.

PLoS One. 2009 Dec 15;4(12):e8314. doi: 10.1371/journal.pone.0008314.

35.

Gene expression profiling of pulmonary fibrosis identifies Twist1 as an antiapoptotic molecular "rectifier" of growth factor signaling.

Bridges RS, Kass D, Loh K, Glackin C, Borczuk AC, Greenberg S.

Am J Pathol. 2009 Dec;175(6):2351-61. doi: 10.2353/ajpath.2009.080954. Epub 2009 Nov 5.

36.

TWIST family of basic helix-loop-helix transcription factors mediate human mesenchymal stem cell growth and commitment.

Isenmann S, Arthur A, Zannettino AC, Turner JL, Shi S, Glackin CA, Gronthos S.

Stem Cells. 2009 Oct;27(10):2457-68. doi: 10.1002/stem.181.

37.

Neural stem cell tropism to glioma: critical role of tumor hypoxia.

Zhao D, Najbauer J, Garcia E, Metz MZ, Gutova M, Glackin CA, Kim SU, Aboody KS.

Mol Cancer Res. 2008 Dec;6(12):1819-29. doi: 10.1158/1541-7786.MCR-08-0146.

38.

CCAAT/enhancer binding protein delta up-regulates aromatase promoters I.3/II in breast cancer epithelial cells.

Kijima I, Ye J, Glackin C, Chen S.

Cancer Res. 2008 Jun 1;68(11):4455-64. doi: 10.1158/0008-5472.CAN-07-3249.

39.

Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.

Gutova M, Najbauer J, Frank RT, Kendall SE, Gevorgyan A, Metz MZ, Guevorkian M, Edmiston M, Zhao D, Glackin CA, Kim SU, Aboody KS.

Stem Cells. 2008 Jun;26(6):1406-13. doi: 10.1634/stemcells.2008-0141. Epub 2008 Apr 10.

40.

Neural stem cell targeting of glioma is dependent on phosphoinositide 3-kinase signaling.

Kendall SE, Najbauer J, Johnston HF, Metz MZ, Li S, Bowers M, Garcia E, Kim SU, Barish ME, Aboody KS, Glackin CA.

Stem Cells. 2008 Jun;26(6):1575-86. doi: 10.1634/stemcells.2007-0887. Epub 2008 Mar 13.

41.

Meta-analysis of breast cancer microarray studies in conjunction with conserved cis-elements suggest patterns for coordinate regulation.

Smith DD, Saetrom P, Snøve O Jr, Lundberg C, Rivas GE, Glackin C, Larson GP.

BMC Bioinformatics. 2008 Jan 28;9:63. doi: 10.1186/1471-2105-9-63.

42.

Development of a tumor-selective approach to treat metastatic cancer.

Aboody KS, Bush RA, Garcia E, Metz MZ, Najbauer J, Justus KA, Phelps DA, Remack JS, Yoon KJ, Gillespie S, Kim SU, Glackin CA, Potter PM, Danks MK.

PLoS One. 2006 Dec 20;1:e23.

43.

Twist overexpression promotes chromosomal instability in the breast cancer cell line MCF-7.

Vesuna F, Winnard P Jr, Glackin C, Raman V.

Cancer Genet Cytogenet. 2006 Jun;167(2):189-91. No abstract available. Erratum in: Cancer Genet Cytogenet. 2006 Nov;171(1):81.

44.

N-cadherin gene expression in prostate carcinoma is modulated by integrin-dependent nuclear translocation of Twist1.

Alexander NR, Tran NL, Rekapally H, Summers CE, Glackin C, Heimark RL.

Cancer Res. 2006 Apr 1;66(7):3365-9.

45.

Stable integration of an empty vector in MCF-7 cells greatly alters the karyotype.

Winnard P Jr, Glackin C, Raman V.

Cancer Genet Cytogenet. 2006 Jan 15;164(2):174-6. No abstract available.

PMID:
16434326
46.

Twist overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer.

Mironchik Y, Winnard PT Jr, Vesuna F, Kato Y, Wildes F, Pathak AP, Kominsky S, Artemov D, Bhujwalla Z, Van Diest P, Burger H, Glackin C, Raman V.

Cancer Res. 2005 Dec 1;65(23):10801-9.

47.

TWIST is expressed in human gliomas and promotes invasion.

Elias MC, Tozer KR, Silber JR, Mikheeva S, Deng M, Morrison RS, Manning TC, Silbergeld DL, Glackin CA, Reh TA, Rostomily RC.

Neoplasia. 2005 Sep;7(9):824-37.

48.

NRAGE mediates p38 activation and neural progenitor apoptosis via the bone morphogenetic protein signaling cascade.

Kendall SE, Battelli C, Irwin S, Mitchell JG, Glackin CA, Verdi JM.

Mol Cell Biol. 2005 Sep;25(17):7711-24. Erratum in: Mol Cell Biol. 2006 May;26(9):3681.

49.

Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target.

Kwok WK, Ling MT, Lee TW, Lau TC, Zhou C, Zhang X, Chua CW, Chan KW, Chan FL, Glackin C, Wong YC, Wang X.

Cancer Res. 2005 Jun 15;65(12):5153-62.

50.

Twist2, a novel ADD1/SREBP1c interacting protein, represses the transcriptional activity of ADD1/SREBP1c.

Lee YS, Lee HH, Park J, Yoo EJ, Glackin CA, Choi YI, Jeon SH, Seong RH, Park SD, Kim JB.

Nucleic Acids Res. 2003 Dec 15;31(24):7165-74.

Supplemental Content

Loading ...
Support Center